Johnathan Man
Overview
Explore the profile of Johnathan Man including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
822
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cho D, Roncolato F, Man J, Simes J, Lord S, Links M, et al.
JCO Precis Oncol
. 2022 Feb;
1:1-12.
PMID: 35172509
Purpose: The demand for more rapid access to novel biologic therapies than randomized controlled trials can deliver is a topic of ongoing study and debate. We aimed to inform this...
2.
Man J, Millican J, Mulvey A, Gebski V, Hui R
JNCI Cancer Spectr
. 2021 Jun;
5(3).
PMID: 34084999
Background: Expression of programmed cell death ligand 1 (PD-L1) on tumor cells with or without immune cells is widely reported in clinical trials of programmed cell death receptor 1 (PD-1)...
3.
Man J, Ritchie G, Links M, Lord S, Lee C
Asia Pac J Clin Oncol
. 2019 Mar;
15(3):191.
PMID: 30815961
No abstract available.
4.
Purdie S, Creighton N, White K, Baker D, Ewald D, Lee C, et al.
NPJ Prim Care Respir Med
. 2019 Feb;
29(1):2.
PMID: 30737397
Little has been published on the diagnostic and referral pathway for lung cancer in Australia. This study set out to quantify general practitioner (GP) and lung specialist attendance and diagnostic...
5.
Ritchie G, Gasper H, Man J, Lord S, Marschner I, Friedlander M, et al.
JAMA Oncol
. 2018 Feb;
4(4):522-528.
PMID: 29470579
Importance: Checkpoint inhibitors have a unique mechanism of action that differs from chemotherapy or targeted therapies. The validity of objective response rate (ORR) as a surrogate for progression-free survival (PFS)...
6.
Man J, Ritchie G, Links M, Lord S, Lee C
Asia Pac J Clin Oncol
. 2018 Jan;
14(3):141-152.
PMID: 29349927
Background: We performed a meta-analysis to quantify toxic death, adverse events (AEs) and treatment discontinuation due to AEs from checkpoint inhibitors (CI). Methods: We searched for randomized trials with adequate...
7.
Lee C, Man J, Lord S, Cooper W, Links M, Gebski V, et al.
JAMA Oncol
. 2017 Dec;
4(2):210-216.
PMID: 29270615
Importance: Checkpoint inhibitors have replaced docetaxel as the new standard second-line therapy in advanced non-small cell lung carcinoma (NSCLC), but little is known about the potential predictive value of clinical...
8.
Lee C, Man J, Lord S, Links M, Gebski V, Mok T, et al.
J Thorac Oncol
. 2016 Nov;
12(2):403-407.
PMID: 27765535
Introduction: We performed a meta-analysis to assess the role of immune checkpoint inhibitors as second-line therapy in EGFR-mutant advanced NSCLC. Methods: Randomized trials comparing immune checkpoint inhibitors against chemotherapy were...